- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Global Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Results
1870
Strong Balance Sheet Stocks: companies with a Health score of at least 4, ordered by Health score.
1870 companies
Genomed Spólka Akcyjna
Market Cap: zł38.1m
Provides DNA sequencing and analysis, and diagnostics of congenital diseases in Poland.
GEN
zł28.80
7D
5.1%
1Y
4.3%
Genovis AB (publ.)
Market Cap: SEK 1.5b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 22.65
7D
-1.5%
1Y
-19.5%
Genmab
Market Cap: DKK 113.3b
A biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
GMAB
DKK 1,840.50
7D
1.8%
1Y
13.5%
Sera Prognostics
Market Cap: US$112.3m
A women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States.
SERA
US$3.09
7D
-6.4%
1Y
-59.8%
Flerie
Market Cap: SEK 3.2b
A venture capital firm specializing in early-stage investments.
FLERIE
SEK 41.80
7D
0.5%
1Y
-0.5%
Reflect Scientific
Market Cap: US$4.0m
Through its subsidiaries, engages in the design, development, and sale of scientific equipment for the life science and manufacturing industries worldwide.
RSCF
US$0.053
7D
12.8%
1Y
-4.3%
Xenon Pharmaceuticals
Market Cap: US$2.8b
A neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada.
XENE
US$37.98
7D
2.8%
1Y
-1.7%
GRAIL
Market Cap: US$1.7b
A commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
GRAL
US$49.86
7D
19.7%
1Y
246.3%
Bicycle Therapeutics
Market Cap: US$522.6m
A clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
BCYC
US$7.40
7D
6.8%
1Y
-68.1%
InflaRx
Market Cap: US$87.4m
A clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
IFRX
US$1.30
7D
-3.0%
1Y
-17.2%
Psyence Biomedical
Market Cap: US$1.8m
Engages in the development of botanical psilocybin-based psychedelic medicines.
PBM
US$3.11
7D
-34.7%
1Y
-95.2%
RAPT Therapeutics
Market Cap: US$404.3m
Operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States.
RAPT
US$26.38
7D
32.8%
1Y
68.2%
Aura Biosciences
Market Cap: US$365.3m
A clinical-stage biotechnology company, develops precision therapies to treat solid tumors.
AURA
US$6.16
7D
1.3%
1Y
-31.8%
MediciNova
Market Cap: US$60.8m
A biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
MNOV
US$1.27
7D
0%
1Y
-33.5%
Elite Pharmaceuticals
Market Cap: US$670.8m
A specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals.
ELTP
US$0.69
7D
11.2%
1Y
77.4%
Burning Rock Biotech
Market Cap: US$98.1m
Develops and sells cancer therapy selection tests in the People's Republic of China and the United States.
BNR
US$8.93
7D
3.6%
1Y
174.8%
Apogee Therapeutics
Market Cap: US$2.2b
A clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications.
APGE
US$38.22
7D
4.6%
1Y
-34.1%
IDL Diagnostics
Market Cap: SEK 92.6m
A vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden.
IDLDX
SEK 0.40
7D
-2.7%
1Y
-20.4%
Cabaletta Bio
Market Cap: US$211.3m
A clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
CABA
US$2.36
7D
7.8%
1Y
-44.6%
Bio-Techne
Market Cap: US$7.9b
Develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
TECH
US$51.85
7D
-2.4%
1Y
-34.1%
Respiratorius
Market Cap: €21.7m
A research company, develops drug candidates for the treatment of cancer, chronic obstructive pulmonary disease (COPD), and asthma.
HF00
€0.20
7D
-22.4%
1Y
-56.3%
Cidara Therapeutics
Market Cap: US$2.1b
Operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases.
CDTX
US$90.57
7D
31.8%
1Y
743.3%
BIOTON
Market Cap: zł386.4m
A biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally.
BIO
zł4.50
7D
0%
1Y
32.5%
Opus Genetics
Market Cap: US$108.4m
A clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs).
IRD
US$1.82
7D
19.7%
1Y
41.1%
Ipsen
Market Cap: €9.2b
Operates as a biopharmaceutical company worldwide.
IPN
€111.60
7D
-3.0%
1Y
0.09%
CytoMed Therapeutics
Market Cap: US$22.7m
A pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.
GDTC
US$1.99
7D
6.7%
1Y
28.4%
Galapagos
Market Cap: €1.9b
A biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
GLPG
€28.32
7D
-1.7%
1Y
7.3%
SIGA Technologies
Market Cap: US$628.7m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$9.16
7D
4.3%
1Y
31.6%
Coya Therapeutics
Market Cap: US$88.8m
A clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs).
COYA
US$5.49
7D
-0.2%
1Y
-18.8%
Quanterix
Market Cap: US$244.4m
A life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions.
QTRX
US$5.19
7D
-4.4%
1Y
-59.2%
Fulcrum Therapeutics
Market Cap: US$459.8m
A clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
FULC
US$8.84
7D
19.6%
1Y
134.5%
hVIVO
Market Cap: UK£52.4m
Operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America.
HVO
UK£0.077
7D
-22.1%
1Y
-72.8%
Innoviva
Market Cap: US$1.2b
Engages in the development and commercialization of pharmaceutical products in the United States and internationally.
INVA
US$18.86
7D
-1.7%
1Y
-2.4%
Azenta
Market Cap: US$1.3b
Provides biological and chemical compound sample exploration and management solutions for the life sciences market in the United States, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally.
AZTA
US$28.56
7D
-8.1%
1Y
-42.2%
Black Diamond Therapeutics
Market Cap: US$177.1m
A clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.
BDTX
US$3.40
7D
3.7%
1Y
-19.6%
Biomark Diagnostics
Market Cap: €18.1m
Develops early-stage cancer diagnostic technology platform to detect and treat cancer.
20B
€0.17
7D
-11.2%
1Y
18.2%